Cookie policy notice

By continuing to use this site you agree to our cookies policy below:
Since 26 May 2011, the law now states that cookies on websites can ony be used with your specific consent. Cookies allow us to ensure that you enjoy the best browsing experience.

This site is intended for health professionals only

At the heart of general practice since 1960

Dabigatran trial in patients with mechanical valves halted due to excess of bleeding

  • Print
  • Comment
  • Save

Heart-valves

A major anticoagulant trial has had to be halted early due to an excess of thromboembolic and bleeding complications in the dabigatran group, compared with those taking warfarin.

The study in patients recently fitted with mechanical heart valves, adds to the debate surrounding the safety of the new oral anticoagulants.

But it also comes as a separate analysis - published today - suggests the drugs are the ‘most promising treatments’ to reduce cardiovascular events and all-cause mortality in patients with atrial fibrillation.

The RE-ALIGN study - which has just been publised in the NEJM - looked at 252 patients with aortic or mitral valve replacement within the past seven days or  at least three months earlier. They were randomly assigned to receive dabigatran or warfarin.

Major bleeding occurred in seven patients on dabigatran (4%) and two patients (2%) on warfarin. All patients with major bleeding had pericardial bleeding.

Read the full story with more details- plus an update on the dabigatran data so far.

 

Have your say

  • Print
  • Comment
  • Save